Download PDF
Thromb Haemost 2018; 118(01): 090-102
DOI: 10.1160/TH17-05-0330
Coagulation and Fibrinolysis
Schattauer GmbH Stuttgart

Passivating Injured Endothelium with Kinexins in Thrombolytic Therapy

Yunn-Hwa Ma
,
Chao-Wei Huang
,
Chih-Jen Wen
,
Yi-Ching Lu
,
Shiaw-Pyng Wey
,
Tze-Chein Wun
Further Information

Publication History

15 May 2017

10 October 2017

Publication Date:
05 January 2018 (online)

    Permissions and Reprints

Abstract

Without conjunctive administration of an anticoagulant, endothelial injury-induced thrombosis is resistant to thrombolysis and prone to re-thrombosis. We hypothesized that co-delivery of recombinant tissue plasminogen activator (rtPA) with annexin V–containing anticoagulants that specifically target the injured endothelium may passivate the thrombogenic elements of the vascular injury site and enhance rtPA-induced thrombolysis. In this study, the effects of conjunctive administration of Kinexins (Kunitz inhibitor–annexin V fusion proteins) with rtPA on thrombolysis were determined in vitro and in vivo. Thromboelastometry showed that both TAP-A (tick anticoagulant peptide–annexin V fusion protein; an inhibitor of factor Xa [FXa] and prothrombinase) and A-6L15 (annexin V-6L15 fusion protein; an inhibitor of tissue factor/FVIIa) exerted concentration-dependent (10–100 nM) effects on clot formation, with TAP-A being several folds more potent than A-6L15 in whole blood. Combination of TAP-A or A-6L15 with rtPA (1 μg/mL) led to decrease in lysis index, suggesting conjunctive enhancement of thrombolysis by combined use of rtPA with TAP-A or A-6L15. In a rat cremaster muscle preparation subjected to photochemical injury, conjunctive administration of rtPA and TAP-A significantly restored tissue perfusion to 56%, which is approximately two fold of that by rtPA or TAP-A alone. Near-infrared fluorescence images demonstrated local retention of a fluorescent A-6L15-S288 at the injury site, suggesting a targeting effect of the fusion protein. Pharmacokinetic analysis showed that 123I-labelled TAP-A and A-6L15 had initial distribution half-lives (T1/2α) of approximately 6 minutes and elimination half-lives (T1/2β) of approximately 2.3 hours. In conclusion, Kinexins were potentially useful adjunctive agents with rtPA thrombolytic therapy especially for thrombosis induced by endothelial injury.

Keywords

plasminogen activators - thrombolysis - annexin V - kunitz protease inhibitor - anticoagulants

Author Contributions

Y.-H.M. is responsible for the experimental design, writing and funding of the work; C.-W.H. conducted most of the experiments and analysis in this study as his master's thesis; C.-J.W. contributed to verifying the targeting effects of A-6L15; Y.-C.L. designed and conducted the pharmacokinetic study; S.-P.W. designed and supervised all studies involving radioactive materials; T.-C.W. synthesized Kinexins and actively participated in discussion and writing of this work.


Supplementary Material

 

  • References

  • 1 Rutherford JD, Braunwald E. Thrombolytic therapy in acute myocardial infarction. Chest 1990; 97 (4, Suppl): 136S-145S
    CrossrefPubMedGoogle Scholar
  • 2 Solhpour A, Yusuf SW. Fibrinolytic therapy in patients with ST-elevation myocardial infarction. Expert Rev Cardiovasc Ther 2014; 12 (02) 201-215
    CrossrefPubMedGoogle Scholar
  • 3 National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995; 333 (24) 1581-1587
    CrossrefPubMedGoogle Scholar
  • 4 Röther J, Ford GA, Thijs VNS. Thrombolytics in acute ischaemic stroke: historical perspective and future opportunities. Cerebrovasc Dis 2013; 35 (04) 313-319
    CrossrefPubMedGoogle Scholar
  • 5 Jaff MR, McMurtry MS, Archer SL. , et al. Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a scientific statement from the American Heart Association. Circulation 2011; 123 (16) 1788-1830
    CrossrefPubMedGoogle Scholar
  • 6 Anderson JL, Halperin JL, Albert NM. , et al. Management of patients with peripheral artery disease (compilation of 2005 and 2011 ACCF/AHA guideline recommendations): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013; 127 (13) 1425-1443
    CrossrefPubMedGoogle Scholar
  • 7 Baskin JL, Reiss U, Wilimas JA. , et al. Thrombolytic therapy for central venous catheter occlusion. Haematologica 2012; 97 (05) 641-650
    CrossrefPubMedGoogle Scholar
  • 8 Bang NU, Wilhelm OG, Clayman MD. After coronary thrombolysis and reperfusion, what next?. J Am Coll Cardiol 1989; 14 (04) 837-849
    CrossrefPubMedGoogle Scholar
  • 9 Ohman EM, Califf RM, Topol EJ. , et al. Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction. Circulation 1990; 82 (03) 781-791
    CrossrefPubMedGoogle Scholar
  • 10 Yao SK, Ober JC, Ferguson JJ. , et al. Combination of inhibition of thrombin and blockade of thromboxane A2 synthetase and receptors enhances thrombolysis and delays reocclusion in canine coronary arteries. Circulation 1992; 86 (06) 1993-1999
    CrossrefPubMedGoogle Scholar
  • 11 Pollack Jr C. Pharmacological and mechanical revascularization strategies in STEMI: integration of the two approaches. J Invasive Cardiol 2008; 20 (05) 231-238
    PubMedGoogle Scholar
  • 12 Brieger D. Optimizing adjunctive antithrombotic therapy in the treatment of acute myocardial infarction: a role for low-molecular-weight heparin. Clin Cardiol 2004; 27 (01) 3-8
    PubMedGoogle Scholar
  • 13 Gurewich V. Why so little progress in therapeutic thrombolysis? The current state of the art and prospects for improvement. J Thromb Thrombolysis 2015; 40 (04) 480-487
    CrossrefPubMedGoogle Scholar
  • 14 Sairanen T, Strbian D, Ruuskanen R. , et al. Symptomatic intracranial haemorrhage after thrombolysis with adjuvant anticoagulation in basilar artery occlusion. Eur J Neurol 2015; 22 (03) 493-499
    CrossrefPubMedGoogle Scholar
  • 15 Nicolini FA, Lee P, Malycky JL. , et al. Selective inhibition of factor Xa during thrombolytic therapy markedly improves coronary artery patency in a canine model of coronary thrombosis. Blood Coagul Fibrinolysis 1996; 7 (01) 39-48
    CrossrefPubMedGoogle Scholar
  • 16 Prager NA, Abendschein DR, McKenzie CR. , et al. Role of thrombin compared with factor Xa in the procoagulant activity of whole blood clots. Circulation 1995; 92 (04) 962-967
    CrossrefPubMedGoogle Scholar
  • 17 Chen HH, Vicente CP, He L. , et al. Fusion proteins comprising annexin V and Kunitz protease inhibitors are highly potent thrombogenic site-directed anticoagulants. Blood 2005; 105 (10) 3902-3909
    CrossrefPubMedGoogle Scholar
  • 18 Stassen JM, Lambeir AM, Matthyssens G. , et al. Characterisation of a novel series of aprotinin-derived anticoagulants. I. In vitro and pharmacological properties. Thromb Haemost 1995; 74 (02) 646-654
    Article in Thieme ConnectPubMedGoogle Scholar
  • 19 Jordan SP, Waxman L, Smith DE. , et al. Tick anticoagulant peptide: kinetic analysis of the recombinant inhibitor with blood coagulation factor Xa. Biochemistry 1990; 29 (50) 11095-11100
    CrossrefPubMedGoogle Scholar
  • 20 Krishnaswamy S, Vlasuk GP, Bergum PW. Assembly of the prothrombinase complex enhances the inhibition of bovine factor Xa by tick anticoagulant peptide. Biochemistry 1994; 33 (25) 7897-7907
    CrossrefPubMedGoogle Scholar
  • 21 Kenet G, Stenmo CB, Blemings A. , et al. Intra-patient variability of thromboelastographic parameters following in vivo and ex vivo administration of recombinant activated factor VII in haemophilia patients. A multi-centre, randomised trial. Thromb Haemost 2010; 103 (02) 351-359
    Article in Thieme ConnectPubMedGoogle Scholar
  • 22 Ma YH, Chen SY, Tu SJ. , et al. Manipulation of magnetic nanoparticle retention and hemodynamic consequences in microcirculation: assessment by laser speckle imaging. Int J Nanomedicine 2012; 7: 2817-2827
    PubMedGoogle Scholar
  • 23 Lee H, Mason JC, Achilefu S. Heptamethine cyanine dyes with a robust C-C bond at the central position of the chromophore. J Org Chem 2006; 71 (20) 7862-7865
    CrossrefPubMedGoogle Scholar
  • 24 Halvorsen S, Huber K. Fibrinolytic treatment of ST-elevation myocardial infarction. Update 2014. Hamostaseologie 2014; 34 (01) 47-53
    Article in Thieme ConnectPubMedGoogle Scholar
  • 25 Gershlick AH, Banning AP, Myat A. , et al. Reperfusion therapy for STEMI: is there still a role for thrombolysis in the era of primary percutaneous coronary intervention?. Lancet 2013; 382 (9892): 624-632
    CrossrefPubMedGoogle Scholar
  • 26 Owen J, Friedman KD, Grossman BA. , et al. Thrombolytic therapy with tissue plasminogen activator or streptokinase induces transient thrombin activity. Blood 1988; 72 (02) 616-620
    PubMedGoogle Scholar
  • 27 Eisenberg PR, Sherman L, Rich M. , et al. Importance of continued activation of thrombin reflected by fibrinopeptide A to the efficacy of thrombolysis. J Am Coll Cardiol 1986; 7 (06) 1255-1262
    CrossrefPubMedGoogle Scholar
  • 28 Fitzgerald DJ, Fitzgerald GA. Role of thrombin and thromboxane A2 in reocclusion following coronary thrombolysis with tissue-type plasminogen activator. Proc Natl Acad Sci U S A 1989; 86 (19) 7585-7589
    CrossrefPubMedGoogle Scholar
  • 29 Liao MH, Jan TR, Chiang CC. , et al. Investigation of a potential scintigraphic tracer for imaging apoptosis: radioiodinated annexin V-Kunitz protease inhibitor fusion protein. J Biomed Biotechnol 2011; 2011: 675701
    PubMedGoogle Scholar
  • 30 Yeh YH, Chang SH, Chen SY. , et al. Bolus injections of novel thrombogenic site-targeted fusion proteins comprising annexin-V and Kunitz protease inhibitors attenuate intimal hyperplasia after balloon angioplasty. Int J Cardiol 2017; 240: 339-346
    CrossrefPubMedGoogle Scholar
  • 31 Whiting D, DiNardo JA. TEG and ROTEM: technology and clinical applications. Am J Hematol 2014; 89 (02) 228-232
    CrossrefPubMedGoogle Scholar
  • 32 Campello E, Farina F, Spiezia L. , et al. Thromboelastometry profiles in patients undergoing thrombolytic therapy for acute ischaemic stroke. Thromb Haemost 2016; 115 (06) 1231-1234
    Article in Thieme ConnectPubMedGoogle Scholar
  • 33 Schöchl H, Forster L, Woidke R. , et al. Use of rotation thromboelastometry (ROTEM) to achieve successful treatment of polytrauma with fibrinogen concentrate and prothrombin complex concentrate. Anaesthesia 2010; 65 (02) 199-203
    CrossrefPubMedGoogle Scholar
  • 34 Howard BM, Kornblith LZ, Cheung CK. , et al. Inducing acute traumatic coagulopathy in vitro: the effects of activated protein C on healthy human whole blood. PLoS One 2016; 11 (03) e0150930
    CrossrefPubMedGoogle Scholar
  • 35 Capila I, VanderNoot VA, Mealy TR. , et al. Interaction of heparin with annexin V. FEBS Lett 1999; 446 (2-3): 327-330
    CrossrefPubMedGoogle Scholar
  • 36 Capila I, Hernáiz MJ, Mo YD. , et al. Annexin V–heparin oligosaccharide complex suggests heparan sulfate–mediated assembly on cell surfaces. Structure 2001; 9 (01) 57-64
    CrossrefPubMedGoogle Scholar
  • 37 Ida M, Satoh A, Matsumoto I. , et al. Human annexin V binds to sulfatide: contribution to regulation of blood coagulation. J Biochem 2004; 135 (05) 583-588
    CrossrefPubMedGoogle Scholar
  • 38 Verstraete M. Clinical application of inhibitors of fibrinolysis. Drugs 1985; 29 (03) 236-261
    CrossrefPubMedGoogle Scholar
  • 39 Mangano DT, Tudor IC, Dietzel C. , et al. The risk associated with aprotinin in cardiac surgery. N Engl J Med 2006; 354 (04) 353-365
    CrossrefPubMedGoogle Scholar